Litcius/Paper detail

Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication

Johanna Theruvath, Marie Ménard, Benjamin Smith, Miles H. Linde, Garry L. Coles, Guillermo Nicolás Dalton, Wei Wu, Louise Kiru, Alberto Delaidelli, Elena Sotillo, John L. Silberstein, Anna C. Geraghty, Allison Banuelos, Molly Radosevich, Shaurya Dhingra, Sabine Heitzeneder, Aidan M. Tousley, John Lattin, Peng Xu, Jing Huang, Nicole Nasholm, Andy He, Tracy C. Kuo, Emma Sangalang, Jaume Pons, Amira Barkal, Rachel Brewer, Kristopher D. Marjon, José G. Vilches-Moure, Payton L. Marshall, Ricardo A. Fernandes, Michelle Monje, Jennifer R. Cochran, Poul H. Sorensen, Heike E. Daldrup‐Link, Irving L. Weissman, Julien Sage, Ravindra Majeti, Carolyn R. Bertozzi, William A. Weiss, Crystal L. Mackall, Robbie G. Majzner

2022Nature Medicine255 citationsDOIOpen Access PDF

Topics & Concepts

CD47BlockadeCalreticulinCancer researchMonoclonal antibodyNeuroblastomaMedicineMacrophageImmunotherapyTumor microenvironmentImmunologyCancerAntibodyBiologyReceptorImmune systemInternal medicineCell cultureCell biologyTumor cellsIn vitroBiochemistryGeneticsEndoplasmic reticulumNeuroblastoma Research and TreatmentsPhagocytosis and Immune RegulationErythrocyte Function and Pathophysiology
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication | Litcius